All Title Author
Keywords Abstract

Use of Vasopressive Amines in a Limited Resource Country

DOI: 10.4236/oalib.1104064, PP. 1-9

Keywords: Vasopressor Amines, Acute Cardiac Insufficiency, Cardiogenic Shock

Full-Text   Cite this paper   Add to My Lib


Introduction: Vasopressive amines are frequently used in cardioology. The aim of our work was to evaluate the practical modalities of use of amines in the cardiology department of University Hospital Yalgado Ouédraogo. Patients and Methods: We conducted a prospective observational study for 6 months, from 01 June to 31 November 2013, including all patients treated with vasopressive amines. We were interested in the different clinical pictures, the indications, the choice of amines, and the practical application of the treatment. Results: Fifty patients were included in the study; the mean age was 58 ± 17.6. The sex ratio was 0.85. Hypertensive heart disease was the underlying cardiac disease in 34% of cases. A known chronic heart failure was observed in 62% of cases. Clinical admission tables were dominated by overall heart failure (74%). Vascular collapse (38%) and shock (36%) were the main indications of treatment. Severe alterations in left ventricular systolic function were found in 74% of cases. Dobutamine was the amine of choice (90%). The average time to start treatment was 96.32 minutes (range 15-660 minutes). The time to relay between syringes was more than ten minutes in 72% of the cases, and the nurses’ unavailability was the main cause. Monitoring was manual in almost all cases. The average duration of treatment was 6.64 days. Treatment-related incidents were observed in 26% of cases. The intra-hospital mortality of patients with amines was 48%. Conclusion: The indications of vasopressive amines in the cardiology department are close to the international recommendations. But this treatment suffers in its practical application. The duration of treatment remains excessive but is explained by the lack of therapeutic alternative.


[1]  Teerlink, J.R., Metra, M., Zaca, V., et al. (2009) Agents with Inotropic Properties for the Management of Acute Heart Failure Syndromes. Traditional Agents and Beyond. Heart Failure Reviews, 14, 243-253.
[2]  Rusca, M. and Liaudet, L. (2009) Place of Treatment with Inotropic Agents Positive in Acute Heart Failure in Intensive Care. Revue Medicale de la Suisse Romande, 5, 2512-2515.
[3]  Logeart, D. (2013) Acute Heart Failure: Current Status, Registries Data.
[4]  Mebazaa, A. and Payen, D. (2006 Epidemiology of Acute Heart Failure Syndrome. In: Alla, F. and Zannad, F., Eds., Acute Heart Failure, Tsunami, Paris, 19-29.
[5]  Bertrand, E., Muna, W.F.T., Diouf, S.M., et al. (2006) Cardiovascular Emergencies in Sub-Saharan Africa. Archives of Heart Diseases and Vessels, 9, 1159-1165.
[6]  Gombet, Th., Ellenga-Mbolla, B.F., Ikama, M., et al. (2007) Cardiovascular Emergencies at the Hospital and University Center of Brazzaville. Black African Medicine, 59, 5005-5011.
[7]  Ikama, M.S., Kimbally-Kaky, G., Gombet, T., et al. (2008) Heart Failure of Old Man in Brazzaville: Clinical, Etiological and Progressive Aspects.. Tropical Medicine, 68, 257-260.
[8]  Parissis, J.T., Farmakis, D. and Nieminen, M. (2007) Classical Inotropes and New Cardiac Enhancers. Heart Failure Reviews, 12, 149-156.
[9]  ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration with the International Society for Heart and Lung Transplantation. Circulation, 119, 1977-2016
[10]  ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in Collaboration with the Heart Failure Association of the ESC (HFA) and Endorsed by the European Society of Intensive Care Medicine (ESICM) (2008). European Journal of Heart Failure, 10, 933-989.
[11]  ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2012). European Heart Journal, 33, 1787-1847
[12]  Besse, L. and Lacotte (2004). Beta-Adrenergic Agonists: Adrenaline, Dobutamine, Dopamine. In: Cardiology and Resuscitation, Vernazobres-Grego, Paris, 392-394.
[13]  Lamirault, G., Gueffet, J.P., Pattier, S., Sokic, C., et al. (2006) What Drug Therapy to Offer to Patients with Advanced Heart Failure? Réal Cardio, 220.
[14]  Gueugniaud, P.Y., Macabeo, C., Ruiz, J. and Zeghari, M. (2002) Catecholamines in Shock States. SFAR 2001.
[15]  Regad, D., Chabert, B., Chamussy, C., et al. (2011) Contribution of Automation of Electric Catecholamine Syringe Relays in Nursing. Réanimation, 20, 247-250.
[16]  Ricard, J.D., Martin, Y., Botcherby, C., et al. (2011) Catecholamine Relay in Intensive Care. Réanimation, 20, 138-142.
[17]  Tacon, C.L., Mc Caffrey, J. and Delaney, A. (2012) Dobutamine for Patients with Severe Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Intensive Care Medicine, 38, 359-367.
[18]  Gheorghiade, M., Vaduganathan, M., Ambrosy, A., et al. (2013) Current Management and Future Directions for the Treatment of Patients Hospitalized for Heart Failure with Low Blood Pressure. Heart Failure Reviews, 18, 107-122.


comments powered by Disqus